A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Bermekimab (Primary) ; Dupilumab
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms GENESIS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 20 Apr 2022 This trial has been completed in Germany (End Date: 31 March 2022) according to European Clinical Trials Database record.
- 15 Apr 2022 This trial was completed in Germany (global end date: 2022-03-31), according to European Clinical Trials Database record.
- 07 Apr 2022 Status changed from active, no longer recruiting to discontinued.